Background-Whether intralesional abciximab administration and thrombus aspiration confer clinical benefits to patients undergoing primary percutaneous coronary intervention for ST-segment-elevation myocardial infarction is controversial. Methods and Results-A total of 452 patients with ST-segment-elevation myocardial infarction caused by proximal or mid left anterior descending artery occlusion undergoing primary percutaneous coronary intervention with bivalirudin anticoagulation were randomized in a 2×2 factorial design to bolus abciximab delivered locally at the infarct lesion site versus no abciximab and to manual thrombus aspiration versus no aspiration. Treatment with intralesional abciximab, thrombus aspiration, or both therapies compared with no active therapy before stent implantation resulted in lower 1-year rates of death (4.5% versus 10.4%; P=0.03), severe heart failure (4.2% versus 10.3%; P=0.02), and stent thrombosis (0.9% versus 3.8%; P=0.046). Between 30 days and 1 year of follow-up, treatment with intralesional abciximab compared with no abciximab was associated with a lower rate of death (1.4% versus 4.9%; P=0.04) and composite major adverse ischemic events (3.3% versus 7.8%; P=0.04), with nonsignificantly different overall 1-year rates of mortality, composite ischemic events, and heart failure-related events. Thrombus aspiration compared with no aspiration was associated with lower rates of new-onset severe heart failure between 30 days and 1 year (0.9% versus 4.5%; P=0.02) and of rehospitalization for heart failure from randomization to 1 year (0.9% versus 5.4%; P=0.0008), with nonsignificantly different rates of mortality. Conclusions-Intralesional abciximab and thrombus aspiration may have long-term benefits in patients with anterior STsegment-elevation myocardial infarction presenting early after symptom onset and undergoing primary percutaneous coronary intervention with bivalirudin anticoagulation. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT00976521.
D espite restoration of normal epicardial coronary flow, myocardial recovery after primary percutaneous coronary intervention (PCI) in patients with ST-segment-elevation myocardial infarction (STEMI) is often suboptimal, resulting in increased rates of heart failure and death. [1] [2] [3] Although the mechanisms underlying impaired myocardial recovery after primary PCI are multifactorial, thrombus embolization resulting in impaired microvascular perfusion is thought to be a leading cause. 4, 5 Two approaches to decrease distal embolization are bolus administration of intracoronary abciximab and thrombus aspiration. Beyond their effects in inhibiting platelet cross-linking, glycoprotein IIb/IIIa inhibitors may directly dissolve platelet aggregates in a dose-dependent manner. 6 By achieving high local drug concentrations, intracoronary abciximab may be more effective in reducing platelet thromboemboli than when administered intravenously. 7, 8 However, after small-to moderate-sized studies of intracoronary abciximab reported improved myocardial perfusion and reduced infarct size, 9, 10 a large-scale pivotal trial found neither greater myocardial salvage nor improved event-free survival with intracoronary compared with intravenous abciximab. 11, 12 A possible reason why intracoronary abciximab may have failed was delivery of the glycoprotein IIb/IIIa inhibitor through the guide catheter, allowing backflow into the aorta or preferential flow into nonoccluded vessels, potentially diminishing the amount of drug delivered to the infarct lesion. To avoid these limitations, abciximab may be delivered directly to the infarct lesion site through a drug delivery catheter and when delivered in this manner reduces thrombus to a greater extent than when given through the guide catheter. 13 Conflicting data on the efficacy of thrombus aspiration have also been reported, with the positive results from single-center studies not confirmed in multicenter trials. 14, 15 Nor have studies of thrombus aspiration demonstrated improved in-stent flow areas after primary PCI 16 or reduced infarct size, 17 the presumed mechanism through which clinical benefit would be realized.
Most previous studies of intracoronary abciximab and thrombus aspiration have enrolled patients with a small amount of myocardium at risk (eg, nonanterior MI) and those presenting >6 hours after infarct onset, well beyond the time window for effective myocardial salvage. 18 To overcome these limitations, we performed the INFUSE-AMI trial, in which 452 patients presenting early with STEMI because of an occluded proximal or mid left anterior descending (LAD) coronary artery were randomized before PCI to intralesional delivery of a bolus dose of abciximab versus no abciximab and to thrombus aspiration versus no aspiration. 19 All patients received bivalirudin without a postprocedural abciximab infusion to minimize bleeding and improve survival. 20, 21 As previously reported, the 30-day infarct size primary end point, as assessed by cardiac MRI (CMRI), was reduced by intralesional abciximab but not by thrombus aspiration. 22 No significant differences in the rates of adverse events at 30 days were present between the groups. We herein report the final 1-year results from the INFUSE-AMI trial. A secondary goal of the present report was to examine the relationship between 30-day infarct size and subsequent clinical outcomes to 1 year.
Methods

Protocol and Patients
As previously described, 19 INFUSE-AMI was an open-label, 2×2 factorial, prospective, randomized, multicenter, single-blind trial of bolus intralesional abciximab administration and manual thrombus aspiration in patients undergoing primary PCI for anterior STEMI. Patients aged ≥18 years with ≥1 mm of ST-segment-elevation in ≥2 contiguous leads in V1 through V4 or new left bundle branch block with anticipated symptom onset to device time of ≤5 hours were enrolled. Principal clinical exclusion criteria included prior MI, bypass graft surgery, or LAD stenting; contraindications to study medications, contrast or CMRI; known creatinine clearance <30 mL/min per 1.73 m 2 or dialysis, platelet count <100 000 or >700 000 cells/mm 3 , or hemoglobin <10 g/dL; recent major bleeding, bleeding diathesis, or current warfarin use; history of intracranial disease; ischemic stroke or transient ischemic attack within 6 months or any permanent neurological defect; cardiogenic shock; prior fibrinolysis or glycoprotein IIb/IIIa inhibitors for the present admission; and any comorbid conditions likely to interfere with protocol compliance or associated with <1-year survival. The study was approved by the institutional review board at each participating center, and all eligible patients signed informed written consent.
Patients received aspirin 324 mg PO or 250 to 500 mg IV and clopidogrel 600 mg or prasugrel 60 mg PO before angiography and procedural anticoagulation with bivalirudin (IV bolus 0.75 mg/kg plus infusion of 1.75 mg/kg per hour, discontinued at procedure end) without routine glycoprotein IIb/IIIa inhibition. Angiographic eligibility required a proximal or mid LAD infarct lesion with Thrombolysis In Myocardial Infarction 0 to 2 flow and absence of excessive tortuosity, diffuse disease, heavy calcification, or significant left main disease. Eligible patients were randomized equally to 1 of 4 groups: (1) thrombus aspiration followed by intralesional bolus abciximab;
(2) thrombus aspiration without abciximab; (3) intralesional bolus abciximab without aspiration; or (4) no abciximab and no aspiration. Manual thrombus aspiration was performed with a 6F Export Catheter (Medtronic, Santa Rosa, CA). Intralesional abciximab was administered locally at the site of the infarct lesion via the ClearWay RX Local Therapeutic Infusion Catheter, a microporous weeping polytetrafluoroethylene balloon mounted on a 2.7F rapid exchange catheter (Atrium Medical, Hudson, NH). Abciximab infusion after PCI was allowed only for refractory intraprocedural thrombotic complications. The details of thrombus aspiration and intralesional abciximab infusion have been previously described. 19, 22 Bare-metal or drug-eluting stents were implanted at the discretion of the operator. After PCI, all patients were treated with aspirin indefinitely and clopidogrel or prasugrel for ≥1 year. CMRI was scheduled in all patients at 30 days. Clinical follow-up was scheduled at 30 days and 1 year.
End Points and Definitions
The primary efficacy end point was infarct size measured as a percentage of total left ventricular mass at 30 days using previously described methodology. 22 Major adverse cardiac and heart failure events were defined as death, reinfarction, new-onset severe heart failure, or rehospitalization for heart failure. Major adverse cardiac and cerebrovascular events were defined as death, reinfarction, stroke, or clinically driven target vessel revascularization. Detailed definitions of the clinical end points have been previously published. 19 An independent clinical events committee blinded to randomization adjudicated all major end point events using original source documents.
WhAT IS KNOWN
• Thrombus embolization during primary percutaneous coronary intervention in ST-segment-elevation myocardial infarction reduces myocardial perfusion and increases infarct size.
• No approach designed to reduce distal embolization has been shown to be of clear benefit.
WhAT ThE STUDY ADDS
• Infarct size is a powerful determinant of late (30-day to 1-year) mortality and heart failure after primary percutaneous coronary intervention in ST-segmentelevation myocardial infarction.
• Treatment with intralesional abciximab may improve late outcomes after primary percutaneous coronary intervention in ST-segment-elevation myocardial infarction, in part by reducing infarct size.
• Although reduced infarct size was not seen with thrombus aspiration, fewer heart failure events and readmissions between 30 days and 1 year may occur after aspiration as well.
Statistical Methods
All analyses were performed by intention to treat. Categorical outcomes were compared by χ 2 or Fisher's exact test. Continuous variables are presented as median with interquartile range and were compared by Wilcoxon rank-sum test. Kaplan-Meier time-to-event estimates for clinical outcomes were compared with log-rank test. Among patients in whom the 30-day CMRI study was performed, analyses were performed to determine the effect of infarct size above or below the measured median on 30-day to 1-year clinical events (landmark analysis). All statistical tests were 2-sided and were performed using SAS version 9.2 (SAS Institute, Cary, NC). P<0.05 was considered significant for all statistical tests. Because the clinical end points examined in the present report were not powered or prespecified for hypothesis testing, these results should be considered hypothesis generating.
Results
Patients, Procedures, and Medications
Patient enrollment and study flow are shown in Figure I in the online-only Data Supplement Appendix. One-year follow-up was complete in 429 patients (94.9%), with a similar rate among the 4 randomized groups (P=0.45). The baseline characteristics of the randomized patients were well matched ( Table I in the online-only Data Supplement). The study cohort was high risk, with the infarct lesion in the proximal LAD coronary segment in approximately two thirds of patients. Duration from symptom onset to presentation and door-to-balloon time were short (median 99 and 45 minutes, respectively). Protocol compliance was high, and procedural data have been previously described. 22 Medication use at discharge, 30 days, and 1 year is shown in Table II in the online-only Data Supplement and was similar between the randomized groups. Dual antiplatelet agent adherence was high, and most patients were maintained on β-blockers, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers and statins throughout the 1-year follow-up.
Clinical Outcomes According to Abciximab Randomization
Event rates at 30 days, 1 year, and between 30 days and 1 year (landmark analysis) in patients randomized to intralesional abciximab versus no abciximab (pooled across the thrombus aspiration randomization) are shown in Table 1 and Figure 1 . No significant differences were apparent between the 2 groups at 30 days. Between 30 days and 1 year, there were significantly fewer deaths and less major adverse cardiac and cerebrovascular events in patients assigned to intralesional abciximab. At 1 year, the differences in clinical event rates between the 2 groups were not statistically significant, although the point estimates favored patients receiving intralesional abciximab.
Clinical Outcomes According to Thrombus Aspiration
Event rates at 30 days, 1 year, and between 30 days and 1 year (landmark analysis) in patients randomized to thrombus aspiration versus no aspiration (pooled across the abciximab randomization) are shown in Table 2 and Figure 2 . No significant differences were apparent between the 2 groups at 30 days. Between 30 days and 1 year, significantly fewer heart failure events occurred in patients assigned to thrombus aspiration. From randomization through 1 year, thrombus aspiration was associated with fewer readmissions for heart failure, with nonsignificantly different rates of mortality and other cardiac end points.
Clinical Outcomes With Any Treatment and in the 4 Randomized Groups
Patients treated with intralesional abciximab, thrombus aspiration, or both therapies compared with no active treatment (control) had significantly lower 1-year rates of death, heart failure events, and stent thrombosis ( Table 3 and Figure 3A ). However, the beneficial effects of intralesional abciximab and thrombus aspiration were not additive ( Table 4 and Figure 3B ).
Implications of 30-Day Infarct Size
The median 30-day infarct size was 17% of the total left ventricular mass (n=353). As shown in Table 5 , a strong relationship was present between 30-day infarct size and 1-year rates of mortality and heart failure. After adjusting for age in a Cox proportional hazards regression model, infarct size was an independent predictor of 1-year mortality (hazard ratio [95% confidence interval]= 1.11 [1.01-1.22]; P=0.03). 
Discussion
The INFUSE-AMI trial enrolled patients with large anterior STEMI presenting early in the course of infarction to determine whether an abciximab bolus delivered through the Clear-Way RX catheter to the site of the infarct-related lesion and thrombus aspiration via the 6F Export Catheter could improve up on the results of primary PCI in which bivalirudin was used as the procedural anticoagulant. Intralesional abciximab resulted in a modest reduction in infarct size, whereas infarct size was unaffected by thrombus aspiration. No significant differences in either ischemic or heart failure event rates were present with either therapy at 30 days. The principal findings from this multicenter, prospective, randomized trial at 1 year are that (1) compared with control (stenting of the proximal and mid LAD without specific treatment for thrombus), substantial clinical benefits were present among patients randomized to active treatment, whether intralesional abciximab, thrombus aspiration, or both therapies, in whom lower 1-year rates of death, severe heart failure, and stent thrombosis were evident;
(2) bolus intralesional abciximab delivered via the ClearWay RX catheter was associated with lower rates of mortality and ischemic major adverse cardiac and cerebrovascular events between 30 days and 1 year, with nonsignificant trends present for improved outcomes from the time of randomization to the end of the follow-up period; (3) thrombus aspiration performed with the 6F Export Catheter was also associated with improved event-free survival between 30 days and 1 year, with fewer heart failure events and readmissions; and (4) a strong relationship was present between infarct size measured at 30 days and the subsequent development of heart failure and death, which may explain some but not all of the benefits of the active treatments observed in this randomized trial. The extent of myonecrosis is significantly greater in patients with STEMI resulting from occlusion of LAD compared with non-LAD coronary arteries 23 and results in higher rates of heart failure and death. 24, 25 Among patients with anterior compared with nonanterior MI in the HORIZONS-AMI trial, mortality occurred in 7.8% versus 3.3% of patients, respectively, at 1 year (P<0.0001) and in 11.6% versus 5.6% of patients at 3 years (P<0.0001; G.W. Stone, MD, unpublished data 2013). In the present study in which all primary PCI patients were treated with bivalirudin, despite their early presentation (median, 99 minutes) and rapid door-to-balloon times (median, 45 minutes), median infarct size at 30 days was 17% 20, 26 impaired myocardial perfusion as measured by either reduced myocardial blush or persistent ST-segment -elevation is present in only approximately half of patients and is associated with larger infarct size and early and late mortality. 1, 2 Diminished myocardial perfusion after primary PCI is also more likely to occur in LAD compared with non-LAD infarcts, contributing to their worsened prognosis. 1, 2, 24, 25 As distal embolization of thrombus and friable atheromatous debris is thought to be ubiquitous after primary PCI in STEMI and results in capillary block of the distal vascular bed, preventing this occurrence might be expected to reduce infarct size and improve event-free survival. 4, 5 In this regard, perhaps the most important finding from the present trial is that treatment of patients with an occluded proximal or mid LAD with intralesional abciximab, thrombus aspiration, or both therapies before stent implantation was strongly associated with reduced 1-year rates of heart failure, stent thrombosis, and death compared with stenting alone.
Given the modest sample size of the present study and its 2×2 design, overly interpreting differences between the 2 approaches (intralesional abciximab and thrombus aspiration) should be avoided, although each therapy may have different beneficial effects. Specifically, intralesional abciximab reduced infarct size at 30 days (the primary powered end point of the INFUSE-AMI trial), and although clinical benefits were not evident in this early period, fewer patients treated with intralesional abciximab died between 30 days and 1 year compared with patients not receiving such treatment. The fact that mortality was not reduced with intralesional abciximab within the first 30 days but was thereafter suggests that the initial myocardial insult from the large amount of myocardium at risk in anterior STEMI (which may include an extended period of left ventricular dysfunction caused by myocardial stunning before recovery) may dictate the early prognosis (as a result of heart failure and arrhythmic complications), whereas after 30 days reduced infarct size with greater myocardial recovery translates to improved late survival. The fact that 30-day infarct size as measured by CMRI was strongly predictive of subsequent death and heart failure (confirming and extending the findings from earlier studies) 27, 28 and was reduced with intralesional abciximab supports this contention. These findings highlight the importance of long-term follow-up after therapies designed to enhance myocardial recovery to fully appreciate potential clinical benefits. In addition, the differences between intralesional abciximab (which reduced infarct size and mortality after 30 days in the present study) and intracoronary abciximab delivered through the guide catheter (which did not reduce infarct size or late mortality in the AIDA-STEMI trial) 11, 12 bear emphasizing, although a large-scale randomized trial of intralesional abciximab is required to confirm its safety and effectiveness. Perhaps more surprising was the observation that despite the fact that thrombus aspiration did not reduce 30-day infarct size, after this period fewer episodes of severe heart failure and readmissions for heart failure were observed in patients treated with thrombus aspiration. Although caution is again warranted given sample size considerations, these observations suggest that different mechanisms may underlie the potential clinical benefits of thrombus aspiration and intralesional abciximab. The 1-year benefits of thrombus aspiration observed in the present study are consistent with the results from Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS) and a large-scale, single-center propensity-matched experience from the Academic Medical Center in the Netherlands. 14, 29 However, absent evidence of infarct size reduction, the potential pathophysiological mechanisms through which thrombus aspiration might improve longterm outcomes are uncertain. Ultimately, 2 ongoing large-scale trials powered for mortality will determine whether thrombus aspiration before primary PCI is indeed of clinical benefit (NCT01093404 and NCT01149044). Unfortunately, although 30-day infarct size was smallest among patients treated with both intralesional abciximab and thrombus aspiration, clinical evidence for synergy with the 2 therapies was not apparent, although the small number of patients in any one group limits the confidence of such observations. Finally, an alternative promising approach to prevent distal embolization during primary PCI is trapping the friable atherothrombotic material behind a micronet mesh-covered stent, 30 and a large-scale pivotal trial with this device has recently begun (NCT01869738).
Our study has several limitations. Most importantly, the present trial was not powered for clinical end points, and these results must be considered hypothesis generating. Second, randomization was single-blind, and as such some degree of bias cannot be excluded, although the patient, follow-up personnel, core laboratories, and clinical events committee were blinded to treatment assignment. Third, by design we randomized patients with large anterior STEMI presenting early. Whether clinical benefits with intralesional abciximab and thrombus aspiration would be present in patients with smaller infarctions or those presenting late is unknown.
In conclusion, in patients with large anterior STEMI presenting early after infarct onset and undergoing primary PCI with bivalirudin anticoagulation in the INFUSE-AMI trial, infarct size was reduced by abciximab delivered to the site of the infarct lesion, but not by manual thrombus aspiration. Reduced infarct size at 30 days was strongly associated with freedom from subsequent death and heart failure. With followup to 1 year, clinical benefits in terms of reduced rates of cardiac death, heart failure, and stent thrombosis were observed in patients in whom the thrombotic infarct lesion was treated with one or more of these active therapies. As such, intralesional abciximab administration and thrombus aspiration before stent implantation may be recommended in patients with large STEMI presenting early, although large-scale, multicenter randomized trials are required to definitively demonstrate the relative safety and efficacy (as well as cost-effectiveness) of these and other approaches to thrombus during primary PCI.
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